Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.
about
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological SocietyCan mycophenolate mofetil be tapered safely in myasthenia gravis? A retrospective, multicenter analysis.Juvenile myasthenia gravis: a paediatric perspectiveProteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patientsMyasthenia gravis: an update for the clinician.Treatment of myasthenia gravis based on its immunopathogenesisMyasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.Current and emerging treatments for the management of myasthenia gravis.Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.Myasthenia gravis: recent advances in immunopathology and therapy.Two steps forward, one step back: mycophenolate mofetil treatment for myasthenia gravis in the United States.Overview of myasthenia gravis.Treatment of paraneoplastic cerebellar degeneration.Prognostic factors and health-related quality of life in ocular Myasthenia Gravis (OMG).Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, lambert-eaton myasthenic syndrome, and neuromyotonia.Treatment of MuSK-Associated Myasthenia Gravis.Ocular myasthenia gravis: controversies and updates.
P2860
Q26765172-EAD199A2-9FEF-47DF-9B45-CC8F55F718EFQ30300131-C677EC86-4EC2-408F-ABEF-87238AAF90F2Q34029492-AE2B9EEC-6085-426B-9601-01472C96C1A8Q34085747-00A20B9F-9EA0-4A70-803F-8AE6C01B13D8Q34377145-5B72788D-E7EF-42F0-BB96-29DA8D9ED7B6Q35675970-344E1497-8FBA-4BE3-8639-276D7F1C3AF3Q36763355-EA1784D3-64FF-4C88-8E1A-04A3C8B845AFQ37918361-894A2A5C-A8E2-4BAE-8CF5-CE2059175E80Q38801807-FFDFCD32-8CD4-4E75-B73E-8CC1F5812D84Q38969032-035E8CC3-AA65-4409-B77A-64492082E778Q44092529-A6A0EFED-1120-4ED0-BD24-775B68CF4B6DQ44367084-489370B1-769B-497D-971A-F0292327FB0BQ44410712-AADFA814-52FB-4D58-8C2C-511F5DB2749AQ48135299-E3316D35-F20C-4770-BD2F-8D20FB093C83Q53118752-A82D09B9-828C-43A6-8463-6B94F1959B1CQ54379059-893BE37E-2EC6-45FA-90A3-E92ABBC81486Q54394549-E1F45D51-F2C1-4637-A626-4636F7B6857C
P2860
Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Mycophenolate mofetil in AChR- ...... vis: outcomes in 102 patients.
@ast
Mycophenolate mofetil in AChR- ...... vis: outcomes in 102 patients.
@en
type
label
Mycophenolate mofetil in AChR- ...... vis: outcomes in 102 patients.
@ast
Mycophenolate mofetil in AChR- ...... vis: outcomes in 102 patients.
@en
altLabel
Mycophenolate mofetil in AChR- ...... avis: outcomes in 102 patients
@en
prefLabel
Mycophenolate mofetil in AChR- ...... vis: outcomes in 102 patients.
@ast
Mycophenolate mofetil in AChR- ...... vis: outcomes in 102 patients.
@en
P2093
P2860
P356
P1433
P1476
Mycophenolate mofetil in AChR- ...... vis: outcomes in 102 patients.
@en
P2093
Donald B Sanders
Joshua Alpers
Mark R Conaway
Michael K Hehir
Michael Sawa
P2860
P304
P356
10.1002/MUS.21640
P407
P577
2010-05-01T00:00:00Z